The PLACCINE Platform Technology is Conceived to Enable Rapid Development of Vaccines That Can Address a Broad Range of Infectious Agents, including SARS-Associated Coronavirus (SARS-CoV) Patent Filing Claims a Novel Composition of Multiple Antigens and Use of a Synthetic Nano Delivery Technology

Lawrenceville, NJ , Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced

LAWRENCEVILLE, NJ , Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 25,925,925 shares of its common stock at a purchase price of

         Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Phase III OPTIMA Study Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:

LAWRENCEVILLE, N.J. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the third quarter ended September 30, 2020 and provide an update on its development programs for GEN-1, an IL-12

CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox ® Investigator-Sponsored Studies LAWRENCEVILLE, N.J. , Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H.

Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on the OVATION 2 Study with GEN-1 in advanced ovarian cancer patients.

Completes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion’s Capitalization New Agreement Ensures A Strong Balance Sheet and Additional Operating Runway LAWRENCEVILLE, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN)

Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival; Data Maturity at Issue Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , Aug.

LAWRENCEVILLE, N.J , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarter ended June 30, 2020 and provide an update on its development programs for GEN-1, an IL-12 DNA